Deferred Tax Assets, Valuation Allowance in USD of BriaCell Therapeutics Corp. from Q2 2021 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
BriaCell Therapeutics Corp. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q2 2021 to Q2 2025.
  • BriaCell Therapeutics Corp. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Jul 2025 was $24,329,720, a 35% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

BriaCell Therapeutics Corp. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $24,329,720 +$6,295,010 +35% 31 Jul 2025 10-K 16 Oct 2025 2025 FY
Q2 2024 $18,034,710 +$2,114,280 +13% 31 Jul 2024 10-K 16 Oct 2025 2025 FY
Q2 2023 $15,920,430 +$3,790,400 +31% 31 Jul 2023 10-K 29 Oct 2024 2024 FY
Q2 2022 $12,130,030 +$3,766,525 +45% 31 Jul 2022 10-K 25 Oct 2023 2023 FY
Q2 2021 $8,363,505 31 Jul 2021 10-K 28 Oct 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.